Paracrine calcitonin in prostate cancer is linked to CD44 variant expression and invasion

Anticancer Research

Volumn 25, Issue 3 B, 2005, Pages 2075-2083

  Iczkowski, Kenneth A ^a,b   Omara Opyene, A Levi ^a   Kulkarni, Trupti R ^c   Pansara, Megha ^a   Shah, Girish V ^c  

^a UNIVERSITY OF FLORIDA COLLEGE OF MEDICINE   (United States)

^b VETERANS AFFAIRS MEDICAL CENTER   (United States)

^c UNIVERSITY OF LOUISIANA AT MONROE   (United States)

Author keywords

Calcitonin; CD44; G protein; Invasion; Paracrine; Prostate cancer; Signal transduction

Indexed keywords

ADENYLATE CYCLASE; CALCITONIN; CD44V ANTIGEN; CYCLIC AMP; GUANINE NUCLEOTIDE BINDING PROTEIN; GUANINE NUCLEOTIDE BINDING PROTEIN ALPHA SUBUNIT; HERMES ANTIGEN; MESSENGER RNA;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIGEN EXPRESSION; ARTICLE; AUTOCRINE EFFECT; CANCER CELL CULTURE; CANCER INVASION; CONCENTRATION RESPONSE; CONTROLLED STUDY; GENE OVEREXPRESSION; HORMONE DETERMINATION; HUMAN; HUMAN CELL; IN VITRO STUDY; MALE; MOUSE; NONHUMAN; NUDE MOUSE; PARACRINE SIGNALING; PHENOTYPE; PRIORITY JOURNAL; PROSTATE CANCER; PROTEIN BINDING; PROTEIN INTERACTION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SIGNAL TRANSDUCTION; WESTERN BLOTTING;

ADENYLATE CYCLASE; ANIMALS; ANTIGENS, CD44; CALCITONIN; CELL LINE, TUMOR; DOSE-RESPONSE RELATIONSHIP, DRUG; GTP-BINDING PROTEIN ALPHA SUBUNITS, GS; GUANYLYL IMIDODIPHOSPHATE; HUMANS; IN SITU HYBRIDIZATION; MALE; MICE; MICE, NUDE; NEOPLASM INVASIVENESS; PROSTATIC NEOPLASMS; PROTEIN ISOFORMS; RNA, MESSENGER;

EID: 21344456362     PISSN: 02507005     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (33)

1. Iczkowski KA, Pantazis CG, Long J, Noble MJ and Shah GV: Expression of calcitonin-like peptide is increased in prostatic adenocarcinoma. J Urol Pathol 8: 135-147, 1998.
2. 2+ transients. Endocrinology 134: 596-602, 1994.
3. Ritchie CK, Thomas KG, Andrews LR, Tindall DJ and Fitzpatrick LA: Effects of the calcitrophic peptides calcitonin and parathyroid hormone on prostate cancer growth and chemotaxis. Prostate 30: 183-187, 1997.
4. Lin HY, Harris TL, Flannery MS, Aruffo A, Kaji EH, Gorn A, Kolakowski LF Jr, Lodish HF and Goldring SR: Expression cloning of an adenylate cyclase-coupled calcitonin receptor. Science 254: 1022-1024, 1991.
5. Hanna FW, Smith DM, Johnston CF, Akinsanya KO, Jackson ML, Morgan DG, Bhogal R, Buchanan KD and Bloom SR: Expression of a novel receptor for the calcitonin peptide family and a salmon calcitonin-like peptide in the alpha-thyrotropin thyrotroph cell line. Endocrinology 136: 2377-2382, 1995.
6. sα) in proliferation of PC-3M prostate cancer cells. Int J Cancer 91: 46-54, 2001.
7. Chien J, Ren Y, Wang YQ, Bordelon W, Thompson E, Davis R, Rayford W and Shah G: Calcitonin is a prostate epithelium-derived growth stimulatory peptide. Mol Cell Endocrinol 181: 69-79, 2001.
8. sαQL)-mediated signaling increases invasiveness and tumorigenicity of PC-3M prostate cancer cells. Oncogene 18: 3376-3382, 1999.
9. Iczkowski, KA, Pantazis CG and Collins J: The loss of expression of CD44 standard and variant isoforms is related to prostatic carcinoma development and tumor progression. J Urol Pathol 6: 119-129, 1997.
10. Iczkowski KA, Bai S and Pantazis CG: Prostate cancer overexpresses CD44 variants 7-9 at the messenger RNA and protein level. Anticancer Res 23: 3129-3140, 2003.
11. Omara-Opyene AL, Qiu J, Shah G and Iczkowski KA: Prostate cancer invasion is influenced more by expression of a CD44 isoform including variant 9 than by Muc18. Laboratory Investigation 84: 894-907, 2004.
12. sα prostate cancer cells. Mol Biotech 28: 97-103, 2004.
13. Stephenson RA, Dinney CP, Gohji K, Ordonez NG, Killion JJ and Fidler IJ: Metastatic model for human prostate cancer using orthotopic implantation in nude mice. J Natl Cancer Inst 84: 951-957, 1992.
14. T method. Methods 25: 402-408, 2001.
15. Laemmli UK: Cleavage of structural proteins during assembly of the head of bacteriophage T4. Nature 227: 680-685, 1970.
16. Colantonio CM, Kwan W-K, Czerwinski W, Mitchell J and Schimmer BP: Altered G protein activity in a desensitization-resistant mutant of the Y1 adrenocortical tumor cell line. Endocrinology 139: 626-633, 1998.
17. di Sant'Agnese PA: Calcitonin-like immunoreactive and bombesin-like immunoreactive endocrine-paracrine cells of the human prostate. Arch Pathol Lab Med 110: 412-415, 1986.
18. Shah GV, Noble MJ, Austenfeld M, Weigel J, Deftos LJ and Mebust WK: Presence of calcitonin-like immunoreactivity (iCT) in human prostate gland: evidence for iCT secretion by cultured prostate cells. Prostate 21: 87-97, 1992.
19. Rayford W, Noble MJ, Austenfeld MA, Weigel J, Mebust WK and Shah GV: Muscarinic cholinergic receptors promote growth of human prostate cancer cells. Prostate 30: 160-166, 1997.
20. Kim HG, Kassis J, Souto JC, Turner T and Wells A: EGF receptor signaling in prostate morphogenesis and tumorigenesis. Histol Histopathol 14: 1175-1182, 1999.
21. LeRoith D and Roberts CT: The insulin-like growth factor system and cancer. Cancer Lett 195: 127-137, 2003.
22. Wu GJ, Wu MW, Wang SW, Liu Z, Qu P, Peng Q, Yang H, Varma VA, Sun QC, Petros JA, Lim SD and Amin MB: Isolation and characterization of the major form of human MUC18 cDNA gene and correlation of MUC18 over-expression in prostate cancer cell lines and tissues with malignant progression. Gene 279: 17-31, 2001.
23. Wu GJ, Varma VA, Wu MW, Wang SW, Qu P, Yang H, Petros JA, Lim SD and Amin MB: Expression of a human cell adhesion molecule, MUC18, in prostate cancer cell lines and tissues. Prostate 48: 305-315, 2001.
24. Tomita K, van Bokhoven A, van Leenders GJ, Ruijter ET, Jansen CF, Bussemakers MJ and Schalken JA: Cadherin switching in human prostate cancer progression. Cancer Res 60: 3650-3654, 2000.
25. Yoshida K, Goodison S, Sugino T, Bolodeoku J, Churchman M, Warren BF and Tarin D: Semiquantitative detection of abnormal CD44 transcripts in colon carcinomas by reverse transcription-polymerase chain reaction enzyme-linked immunosorbent assay (RT-PCR ELISA). Mol Diagn 1: 167-173, 1996.
26. Matsumura Y, Sugiyama M, Matsumura S, Hayle AJ, Robinson P, Smith JC and Tarin D: Unusual retention of introns in CD44 gene transcripts in bladder cancer provides new diagnostic and clinical oncological opportunities. J Pathol 177: 11-20, 1995.
27. Okamoto I, Morisaki T, Sasaki J, Miyake H, Matsumoto M, Suga M, Ando M and Saya H: Molecular detection of cancer cells by competitive reverse transcription-polymerase chain reaction analysis of specific CD44 variant RNAs. J Natl Cancer Inst 90: 307-315, 1998.
28. Zhang Y, Thant AA, Machida K, Ichigotani Y, Naito Y, Hiraiwa Y, Senga T, Sohara Y, Matsuda S and Hamaguchi M: Activation of pro-gelatinase B by Endometase/Matrilysin-2 promotes invasion of human prostate cancer cells. J Biol Chem 275: 15056-15064, 2003.
29. Dohadwala M, Batra RK, Luo J, Lin Y, Krysan K, Fold M, Sharma S and Dubinett SM: Autocrine/paracrine prostaglandin E2 production by non-small cell lung cancer cells regulates matrix metalloprotease-2 and CD44 in cyclooxygenase-2-dependent invasion. J Biol Chem 277: 50828-50833, 2002.
30. Castellone MD, Celetti A, Guarino V, Cirafici AM, Basolo F, Giannini R, Medico E, Kruhoffer M, Orntoft TF, Curcio F, Fusco A, Melillo RM and Santoro M: Autocrine stimulation by osteopontin plays a pivotal role in the expression of the mitogenic and invasive phenotype of RET/PTC-transformed thyroid cells. Oncogene 23: 2188-2196, 2004.
31. 2+/inositol phosphate signaling pathways. Mol Endocrinol 6: 551-556, 1992.
32. Hoosein NM, Logothetis CJ and Chung LWK: Differential effects of peptide hormones bombesin, vasoactive intestinal polypeptide and somatostatin analog RC-60 on the invasive capacity of human prostatic carcinoma cells. J Urol 149: 1209-1213, 1993.
33. Cho-Chung YS, Park YG, Nesterova M, Lee YN and Cho YS: CRE-decoy oligonucleotide inhibition of gene expression and tumor growth. Mol Cell Biochem 212: 29-34, 2000.